NovaQuest Capital to buy Viamet Pharmaceuticals

NovaQuest Capital Management has agreed to acquire drug developer Viamet Pharmaceuticals. No financial terms were disclosed. Patrick Jordan, a partner at NovaQuest Capital, will become Viamet's interim CEO while Dr. Robert Schotzinger will remain as president and CEO of the Viamet group of companies.

DealsNorth AmericaUSHealthcareBriefs